Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
To characterize the pharmacokinetics (PK) of the injectable intramuscular (IM) long-acting formulation (in situ microparticle, ISM) of risperidone over four IM injections in the gluteal and deltoid muscle at 28-day intervals and at one dose strength (75 mg) in patients with schizophrenia.
Epistemonikos ID: e9c3b783f05c894b3bba18f8c0f04df26071443a
First added on: May 11, 2024